Antitumor property of the active principle of jawaharene
1Department of Pharmacy, Jadavpur University, Calcutta, India.
Cancer Letters
|November 30, 1989
Abstract:
The active principle of Jawaharene (JF1), a mixture of fatty acids, was studied for antitumor properties against Ehrlich Ascites Carcinoma (EAC) and Sarcoma-180 (S-180). Using a Warburg respirometer, respiratory O2-uptake by EAC and S-180 cells was completely inhibited by JF1 at the dose of 100 micrograms ml-1. The in vitro cytotoxicity assay revealed that 100% of JF1-treated tumor cells were killed within 60 min incubation. In vivo, EAC and S-180 ascites tumor development was completely inhibited by JF1 at the dose of 5 mg mouse-1 day-1 X 8.
Insights
Jawaharene (JF1), a fatty acid mixture, demonstrated potent antitumor effects. It completely inhibited tumor cell respiration and killed all tested cancer cells in vitro and in vivo.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Jawaharene (JF1) is a mixture of fatty acids with potential therapeutic applications.
- Ehrlich Ascites Carcinoma (EAC) and Sarcoma-180 (S-180) are established tumor models for cancer research.
Purpose of the Study:
- To investigate the antitumor properties of Jawaharene (JF1) against EAC and S-180.
- To evaluate the effects of JF1 on tumor cell respiration and viability.
Main Methods:
- Warburg respirometry was used to assess oxygen consumption by EAC and S-180 cells.
- In vitro cytotoxicity assays were performed to determine JF1's effect on tumor cell killing.
- In vivo studies evaluated the inhibition of ascites tumor development in mice.
Main Results:
- JF1 completely inhibited respiratory oxygen uptake in EAC and S-180 cells at 100 µg/mL.
- In vitro, JF1 treatment resulted in 100% tumor cell death within 60 minutes.
- In vivo, JF1 administration (5 mg/mouse/day for 8 days) completely prevented EAC and S-180 ascites tumor growth.
Conclusions:
- Jawaharene (JF1) exhibits significant in vitro and in vivo antitumor activity.
- JF1 effectively inhibits tumor cell respiration and proliferation.
- These findings suggest JF1 as a promising candidate for cancer therapy development.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...